These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 29210284)

  • 1. Can Persistence With Cholinesterase Inhibitor Treatment Lower Mortality and Health-Care Costs Among Patients With Alzheimer's Disease? A Population-Based Study in Taiwan.
    Ku LE; Li CY; Sun Y
    Am J Alzheimers Dis Other Demen; 2018 Mar; 33(2):86-92. PubMed ID: 29210284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
    Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
    J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective study of cholinesterase inhibitors for Alzheimer's disease: cerebrovascular disease as a predictor of patient outcomes.
    Charbonneau C; Massoud F; Dorais M; LeLorier J
    Curr Med Res Opin; 2008 Dec; 24(12):3287-94. PubMed ID: 19032117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease.
    Amuah JE; Hogan DB; Eliasziw M; Supina A; Beck P; Downey W; Maxwell CJ
    Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):670-9. PubMed ID: 20583207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease.
    Nordström P; Religa D; Wimo A; Winblad B; Eriksdotter M
    Eur Heart J; 2013 Sep; 34(33):2585-91. PubMed ID: 23735859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholinesterase Inhibitor Utilization: The Impact of Provincial Drug Policy on Discontinuation.
    Fisher A; Carney G; Bassett K; Chappell NL
    Value Health; 2016; 19(5):688-96. PubMed ID: 27565287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort study.
    Gardette V; Andrieu S; Lapeyre-Mestre M; Coley N; Cantet C; Ousset PJ; Grand A; Monstastruc JL; Vellas B
    CNS Drugs; 2010 May; 24(5):431-42. PubMed ID: 20369907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction.
    Shahim B; Xu H; Haugaa K; Zetterberg H; Jurga J; Religa D; Eriksdotter M
    Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):128-136. PubMed ID: 38224338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.
    Wattmo C; Wallin ÅK
    Alzheimers Res Ther; 2017 Aug; 9(1):70. PubMed ID: 28859660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholinesterase inhibitors for Alzheimer's disease.
    Birks J
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD005593. PubMed ID: 16437532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal Associations between Survival in Alzheimer's Disease and Cholinesterase Inhibitor Use, Progression, and Community-Based Services.
    Wattmo C; Londos E; Minthon L
    Dement Geriatr Cogn Disord; 2015; 40(5-6):297-310. PubMed ID: 26335053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic effect of cholinesterase inhibitor therapy: implications for managed care.
    Sano M
    Manag Care Interface; 2004 Aug; 17(8):44-9. PubMed ID: 15471110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France.
    Touchon J; Lachaine J; Beauchemin C; Granghaud A; Rive B; Bineau S
    Eur J Health Econ; 2014 Nov; 15(8):791-800. PubMed ID: 23928827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication.
    Yang YH; Wu MN; Chou PS; Su HC; Lin SH; Sung PS
    Curr Alzheimer Res; 2018 Mar; 15(5):474-481. PubMed ID: 29032750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer's disease: a prospective, observational study of factors affecting survival time from admission to death.
    Wattmo C; Londos E; Minthon L
    BMC Neurol; 2016 Aug; 16(1):156. PubMed ID: 27581368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholinesterase inhibitors for Alzheimer disease: do they provide more than symptomatic benefits?
    Suh GH; Ryu SH; Lee DW; Han C; Ju YS; Kee BS; Lee JN; Bae JN; Choi JH; Kim DJ; Lee NJ; Lee JY; Go HJ; Yi JS; Cho SJ; Jeon YW
    Am J Geriatr Psychiatry; 2011 Mar; 19(3):266-73. PubMed ID: 20808128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease.
    Wattmo C; Londos E; Minthon L
    BMC Neurol; 2014 Sep; 14():173. PubMed ID: 25213579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality.
    Xu H; Garcia-Ptacek S; Jönsson L; Wimo A; Nordström P; Eriksdotter M
    Neurology; 2021 Apr; 96(17):e2220-e2230. PubMed ID: 33741639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
    Lu S; Hill J; Fillit H
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 2-year prospective cohort study of antidementia drug non-persistency in mild-to-moderate Alzheimer's disease in Europe : predictors of discontinuation and switch in the ICTUS study.
    Gardette V; Lapeyre-Mestre M; Piau A; Gallini A; Cantet C; Montastruc JL; Vellas B; Andrieu S;
    CNS Drugs; 2014 Feb; 28(2):157-70. PubMed ID: 24408842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.